Now we know whos getting 23andMes DNA data. Meet Regeneron Pharmaceuticals.

23andMe had all the signs of a success story. The unicorn brand became synonymous with consumer-facing genetic testing, went public, and was once valued at $6 billion.But then, it all came tumbling down. Sales for 23AndMe kits began to fall, attempts to raise new funds hit a wall, the company struggled to find a product that would bring in recurring revenue, and it was still dealing with the fallout from a major data breach.23andMe filed for bankruptcy and put its assets up for sale in March 202